You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
新冠檢測板塊普漲,奧泰生物(688606.SH)20CM漲停

格隆匯3月29日丨新冠檢測板塊普漲,科創板奧泰生物(688606.SH)一字板漲停,明德生物漲停,博拓生物、安旭生物、熱景生物、東方生物、九安醫療等集體走高。

消息面上,上海市人民政府辦公廳印發《上海市全力抗疫情助企業促發展的若干政策措施》提到,加強抗疫物資儲備和供應保障,持續提升核酸快速檢測能力,加強集中隔離房源建設和籌措,支持新冠病毒疫苗和治療藥物進口,引導支持企業參與抗疫應急能力建設,做好後備醫療資源儲備。

個股方面,明德生物近日在互動平台表示,公司新冠抗原檢測試劑有銷往上海的訂單。

此外,奧泰生物預計2022年第一季度實現歸母淨利潤10.3億元至11.9億元,同比增加585.4%至691.87%。公司表示,國內外疫情仍在不斷反覆,公司繼續致力於新冠肺炎疫情防控事業,新冠檢測業務訂單繼續保持穩定增長,導致2022年第一季度公司業績相比2021年同期實現較大幅度增長。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account